🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In this phase 3 trial involving patients with FSGS, sparsentan resulted in a greater reduction in proteinuria than irbesartan, but there was no significant between-group difference in eGFR slope. Read the full trial results: nej.md/3MpV858

Today, with CSL Vifor, we announced that the European Medicine Agency’s (EMA) CHMP recommends approval of the CMA for sparsentan for the treatment of IgAN. Read the full press release. bit.ly/3wwpzSs

CKD3 unofficial women in nephrology - 20+ years of neph connection here and still going strong

Today we announced with CSL Vifor that the European Commission has approved FILSPARI (sparsentan) for the treatment of IgA nephropathy (#IgAN). #InRareForLife Press release: bit.ly/3w9cfUc

Link to the latest podcast from the Rare Kidney Disease Scientific Network. First is Brad Rovin. Second is Jon Barratt. Brad H Rovin Jonathan Barratt medicalaffairs.travere.com/rkd-show/

In our latest GN in Ten episode, Koyal Jain and Kenar Jhaveri chat with Jula Inrig about endothelin, sparsentan, the art & science of clinical trial design, clinical research careers outside academia, and how we got to this "golden era" of neph trials. eu1.hubs.ly/H08RsYt0

"SPARSENTAN as First-line Treatment of Incident Patients With IgAN: Preliminary Findings from the SPARTAN Trial" by Sian Griffin 🏴󠁧󠁢󠁷󠁬󠁳󠁿 🌻 🇺🇦 🌻 🏳️‍⚧️, et al, was presented at WCN'24. Their work was transformed into a visual abstract by #ISNWCN Social Media Team member Fong Voon Ken

#APSselect mouse study from AJP Renal finds the nephropathy drug sparsentan improves changes in the kidney associated with inflammatory genes and pathways: ow.ly/gsgI50RtUt8 CC: Dr. Heddwen Brooks, PhD, AJP-Renal Editor-in-Chief

We are delighted to share abstracts at National Kidney Foundation #SCM24 on our research in #RKD, including analyses comparing the effect of sparsentan as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus RASi in real-world use and in clinical trials in patients with #IgAN.

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings. hcplive.com/view/irbesarta… #NKFClinicals #SCM24 #LateBreakers

“There’s always a little love for the glomerulus,” said Jula Inrig, M.D., CMO of Travere Therapeutics during a podcast with the International Society of Glomerular Disease. Jula talks about her career, Kidney Health Initiative, endothelin physiology, and clinical trials of sparsentan in IgAN and FSGS

JCI Insight - Sparsentan improves glomerular hemodynamics, cell functions and tissue repair in a mouse model of FSGS insight.jci.org/articles/view/…

We are excited to announce that our medicine for the treatment of #IgAnephropathy was granted full approval by the FDA. Today’s approval marks an important milestone in transforming treatment for people living with #RareKidneyDisease. Press release: bit.ly/4eakAr1

For all the years I’ve treated people living with IgAN, today marks a new chapter and brings me profound hope for this patient community that has waited for so long. #InRareForLife

Jula Inrig, MD, Chief Medical Officer at Travere Therapeutics, discusses a clinical trial that tested sparsentan for treatment of IgA nephropathy, compared to traditional RAS inhibitors. #CheckRare #RareDisease #IgANephropathy checkrare.com/clinical-trial…

Today we announced that we’ll present 11 abstracts at the upcoming American Society of Nephrology #ASN24 #KidneyWk in San Diego, CA, later this month on our work in #RareKidneyDisease. #InRareForLife bit.ly/4eUMh7A

“When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced,” writes Jula Inrig, M.D., chief medical officer at Travere. Check out her recent article about #RareKidneyDisease and #IgAnephropathy

We’d like to extend a huge thank you to American Society of Nephrology and to everyone who joined us at #ASN24 #KidneyWk. It was a pleasure coming together and sharing our clinical data and research in #IgAN and #FSGS. Thank you to all those who contributed to another thought-provoking and inspiring

Today we announced that we plan to submit a supplemental New Drug Application (sNDA) to the U.S. FDA for sparsentan in focal segmental glomerulosclerosis (#FSGS). Press release: bit.ly/4gDGTGq #InRareForLife

Happy World Kidney Day linkedin.com/posts/jula-inr…